Literature DB >> 14704558

Posttraumatic obstruction of lacrimal pathways: a retrospective analysis of 58 consecutive naso-orbitoethmoid fractures.

Roberto Becelli1, Giancarlo Renzi, Giuseppe Mannino, Giulio Cerulli, Giorgio Iannetti.   

Abstract

Posttraumatic dacryostenosis represent a troublesome sequela for patients who have sustained centrofacial trauma and can determine complexity in diagnosis and treatment. This article, based on a retrospective analysis of 58 patients with naso-orbitoethmoidal (NOE) trauma, reports the incidence of posttraumatic dacryostenosis and the evolution of such impairments in consideration of fracture type. Experience in diagnosis and treatment is illustrated, and surgical outcomes 6 months after external dacryocystorhinostomy (DCR) are reported. Posttraumatic epiphora was observed in 27 patients with NOE fractures (46.5%). In 10 cases, temporary epiphora was encountered and spontaneous recovery of lacrimal drainage within 5 months was observed. In the remaining 17 cases, permanent epiphora was registered and a frequent association with delayed treatment of facial fracture repair or bone loss in the lacrimal district was found. Surgical reconstruction of lacrimal pathways was performed 6 months after primary surgery, with external DCRs in all 17 patients with epiphora and the presence of nasolacrimal duct obstruction observed with dacryocystorhinography. External DCR with a large rhinostomy achieved a success rate of 94% in the reconstruction of lacrimal drainage. Such a technique proved to be effective in the treatment of posttraumatic dacryostenosis, although patients considered the temporary presence of external scars and stenting material to be a major problem.

Entities:  

Mesh:

Year:  2004        PMID: 14704558     DOI: 10.1097/00001665-200401000-00011

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  15 in total

1.  Periorbital Trauma: A New Classification.

Authors:  Eman Yahya Sadek; Amir Elbarbary; Ikram I Safe
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2019-01-30

Review 2.  Complications and Treatment of Delayed or Inadequately Treated Nasoorbitoethmoid Fractures.

Authors:  Peter S Han; Yohanan Kim; Alan S Herford; Jared C Inman
Journal:  Semin Plast Surg       Date:  2019-04-26       Impact factor: 2.314

Review 3.  Orbital Trauma.

Authors:  Kirkland N Lozada; Patrick W Cleveland; Jesse E Smith
Journal:  Semin Plast Surg       Date:  2019-04-26       Impact factor: 2.314

Review 4.  Midface Fractures I.

Authors:  Matthew Louis; Nikhil Agrawal; Matthew Kaufman; Tuan A Truong
Journal:  Semin Plast Surg       Date:  2017-05       Impact factor: 2.314

5.  Pearls of nasoorbitoethmoid trauma management.

Authors:  Marilyn Nguyen; John C Koshy; Larry H Hollier
Journal:  Semin Plast Surg       Date:  2010-11       Impact factor: 2.314

6.  The incidence of symptomatic acquired lacrimal outflow obstruction among residents of Olmsted County, Minnesota, 1976-2000 (an American Ophthalmological Society thesis).

Authors:  John J Woog
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 7.  [Lacrimal system lacerations and their surgical repair].

Authors:  H G Struck
Journal:  Ophthalmologe       Date:  2009-03       Impact factor: 1.059

8.  Nasolacrimal Obstruction Following the Placement of Maxillofacial Hardware.

Authors:  J Minjy Kang; Evan Kalin-Hajdu; Oluwatobi O Idowu; M Reza Vagefi; Robert C Kersten
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2020-02-20

9.  Nasoorbitoethmoid fractures in a tertiary care hospital of eastern India: A prospective study.

Authors:  Debashish Pati; Niranjan Mishra; Indubhusan Kar; Brundabati Meher; Dipti Samal; Krushna Chandra Rath
Journal:  Natl J Maxillofac Surg       Date:  2021-03-16

10.  Nasal epithelial myoepithelial carcinoma: An unusual cause of epiphora, a case report and review of the literature.

Authors:  Juliette O Flam; Christopher D Brook; Rachel Sobel; John C Lee; Michael P Platt
Journal:  Allergy Rhinol (Providence)       Date:  2015-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.